source
- FDA outlines new onshoring incentives and meeting types for generic drug applicants under GDUFA IVThe FDA released its GDUFA IV commitments, indicating that review timelines for generic drug submissions will remain largely consistent through 2032, mirroring the schedule of the previous five yea…
- Lilly sues over black-market retatrutide; Neurocrine's new obesity drug linked to patient deathsEli Lilly has filed six lawsuits against U.S. companies it says are illegally selling black-market versions of its experimental obesity drug retatrutide. The company alleges the defendants are dist…